The Canadian experience with risperidone for the treatment of schizophrenia: An overview

Journal of Psychiatry and Neuroscience

Volumn 23, Issue 4, 1998, Pages 229-239

  Iskedjian, Michael ^a,c   Hux, Margaret ^a   Remington, Gary J ^b  

^a i3 Global   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^c NONE   (Canada)

Author keywords

Antipsychotic agents; Canada; Outcome assessment (health care); Risperidone; Schizophrenia

Indexed keywords

HALOPERIDOL; RISPERIDONE;

DATA ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG USE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MEDICAL INFORMATION; QUALITY OF LIFE; REVIEW; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; CANADA; HUMANS; RISPERIDONE; SCHIZOPHRENIA;

EID: 0031725332     PISSN: 11804882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. Bland RC. Long term mental illness in Canada: an epidemiological perspective on schizophrenia and affective disorders. Can J Psychiatry 1984;29(3):242-6.
2. Annable L, Jones B, Nair V, Remington G, Williams R. Canadian Alliance for Research on Schizophrenia National Research Strategy. Panel Reports. Panel; Psychopharmacology. J Psychiatry Neurosci 1994;19 (5 Suppl 1):29-33.
3. Ontario Ministry of Health. Hospital statistics 1990/91. Toronto: Publications Ontario; 1991. p. 93.
4. Lehmann HL, Ban TA. The history of the psychopharmacology of schizophrenia. Can J Psychiatry 1997;42(2):152-62.
5. Remington GJ. Novel neuroleptics in schizophrenia: theory and clinical relevance. Can J Psychiatry 1994;39(Suppl 2):S43-S45.
6. Mercier C, Renaud C, King S. A thirty-year retrospective study of hospitalization among severely mentally ill patients. Can J Psychiatry 1994;39(2):95-102.
7. Appleby L, Desai PN, Luchins DJ, Gibbons RD, Hedeker DR. Length of stay and recidivism in schizophrenia: a study of public psychiatric hospital patients. Am J Psychiatry 1993;150(1):72-6.
8. Randhawa J, Riley R. Mental Health Statistics, 1982-83 to 1993-94. Health Rep 1996;7(4):55-61. Statistics Canada, cat. no. 82-003.
9. Brenner HS, Dencker SJ, Goldstein MJ, Hubbard JW, Keegan DL, Kruger G, et al. Defining treatment refractoriness in schizophrenia. Schizophr Bull 1990;16(4):551-61.
10. Collins EJ, Hogan TP, Awad AG. The pharmacoepidemiology of treatment-refractory schizophrenia. Can J Psychiatry 1992;37(3): 192-5.
11. Kane JM. Treatment-resistant schizophrenic patients. J Clin Psychiatry 1996;57(Supp 9):35-40.
12. Bezchlibnik-Butler KZ, Remington GJ. Antiparkinsonian drugs in the treatment of neuroleptic-induced extrapyramidal symptoms. Can J Psychiatry 1994;39(2):74-84.
13. Csernansky JG, Brown K, Hollister LE. Is there drug treatment for negative schizophrenic symptoms? Hosp Formul 1986;21:790-2.
14. Möller HJ, Pelzer E, Kissling W, Riehl T, Wernicke T. Efficacy and tolerability of a new antipsychotic compound (risperidone): results of a pilot study. Pharmacopsychiatry 1991;24:185-9 .
15. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 1988;45:789-96.
16. Meltzer HY, Bastani B, Young Kwon K, Ramirez LF, Burnett S, Sharpe J. A prospective study of clozapine in treatment-resistant schizophrenic patients. Psychopharmacology 1989;99 (Suppl):S68-S72.
17. Casey DE. Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacol Bull 1989;99(Suppl):S47-S53.
18. IMS Canada Data Source Montreal (QC): IMS Canada, 1996.
19. Chouinard G. Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicentre risperidone study. J Clin Psychopharmacol 1995;15(Suppl 1):36S-44S.
20. Chouinard G, Vainer JL, Belanger MC, Turnier L, Beaudry P, Roy JY, et al. Risperidone and clozapine in the treatment of drug-resistant schizophrenia and neuroleptic-induced supersensitivity psychosis. Prog Neuropsychopharmacol Biol Psychiatry 1994;18:1129-41.
21. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, et al. A Canadian multicentre placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25-40.
22. Kopala LC, Fredrikson D, Good KP, Honer WG. Symptoms in neuroleptic-naive, first-episode schizophrenia: response to risperidone. Biol Psychiatry 1996;39(4):296-8.
23. McEvoy JP. Efficacy of risperidone in positive features of schizophrenia. J Clin Psychiatry 1994;55(5 Suppl):18-21.
24. Moller HJ, Muller H, Borison RL, Schooler NR, Chouinard G. A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study. Eur Arch Psychiatry Clin Neurosci 1995;245:45-9.
25. Musser WS, Kirisci L. Critique of the Canadian Multicentre Placebo-Controlled Study of Risperidone and Haloperidol. J Clin Psychopharmacol 1995;15:226-30.
26. Addington D. Risperidone: integrating research and practice. Br J Hosp Med 1994;52: 223-4.
27. Chouinard G, Arnott W. Clinical review of risperidone. Can J Psychiatry 1993;38(Suppl 3):S89-S95.
28. Jones B. Schizophrenia: into the next millennium. Can J Psychiatry 1993;38(Suppl 3):S67-S69.
29. Remington GJ. Clinical considerations in the use of risperidone. Can J Psychiatry 1993; 34:S96-S100.
30. Addington DE, Toews JA, Addington JM. Risperidone and tardive dyskinesia: a case report. J Clin Psychiatry 1995;56:484-5.
31. Risperidone and extra-pyramidal symptoms. [Canadian Adverse Drug Reaction Newsletter]. CMAJ 1995;152(1 Suppl):65-7.
32. Chong SA, Tan CH, Lee HS. Hoarding and clozapine-risperidone combination. Can J Psychiatry 1996;41(5):315-6.
33. Dickson R, Williams R, Dalby JT. Dystonic reaction and relapse with clozapine discontinuation and risperidone initiation. Can J Psychiatry 1944;39:184.
34. Dickson RA, Dalby JT, Williams R, Edwards AL. Risperidone-induced prolactin elevations in premenopausal women with schizophrenia. Am J Psychiatry 1995;152:1102-3.
35. Emes CF, Millson RC. Risperidone-induced priapism. Can J Psychiatry 1994;39:315-6.
36. Jones BD, Purdon SE, Labelle A, Finlayson R. Risperidone treatment for severe negative symptoms. Can J Psychiatry 1994;39:381.
37. Kopala L, Honer WG. Risperidone, serotonergic mechanisms, and obsessive - compulsive symptoms in schizophrenia. Am J Psychiatry 1994;151:1714-5.
38. Kopala LC, Honer WG. Schizophrenia and severe tardive dyskinesia responsive to risperidone. J Clin Psychopharmacol 1994;24(6):430-1.
39. Landry P. Effect of risperidone on polydipsia and hyponatremia in schizophrenia. Can J Psychiatry 1995;40:566-7.
40. Meterissian GB. Risperidone-induced neuroleptic malignant syndrome: a case report and review. Can J Psychiatry 1996;41(1):52-4.
41. O'Croinin F, Zibin T. Hypomania associated with risperidone [letter]. Can J Psychiatry 1995;40(1):51.
42. Purdon SE, Lit W, Labelle A, Jones BD. Risperidone in the treatment of pervasive developmental disorder. Can J Psychiatry 1994;39:400-5.
43. Remington G, Adams M. Risperidone and obsessive - compulsive symptoms. J Clin Psychopharmacol 1994;14:358-9.
44. Stip E, Tourjman V, Lew V, Fabian J, Cormier H, Landry P, et al. "Awakenings" effect with risperidone. Am J Psychiatry 1995;152:1833.
45. Takhar J, Manchanda R. Acute dystonic reaction with risperidone. Can J Psychiatry 1996;41(1):61-2.
46. Addington DE, Jones B, Bloom D, Chouinard G, Remington G, Albright P. Reduction of hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study. Clin Ther 1993;15(5):917-26.
47. Albright PS, Livingstone S, Keegan D, Ingham M, Shrikhande S, Le Lorier J. Reduction of healthcare resource utilization and costs following the use of risperidone for patients with schizophrenia previously treated with standard antipsychotic therapy: A retrospective analysis using the Saskatchewan Health linkable databases. Clin Drug Invest 1996;5:289-99.
48. Chouinard G, Albright PS. Economic and health state utility determinations for schizophrenic patients treated with risperidone and haloperidol. J Clin Psychopharmacol 1997;17(4):298-307.
49. Wasylenki DA. The cost of schizophrenia. Can J Psychiatry 1994;39(Suppl 2):S65-S69.
50. Williams R, Dickson R. Economics of schizophrenia. Can J Psychiatry 1995;40(Suppl 2):S60-S67.
51. Andrew HG, Robertson GS, Matsumura H, Fibiger HC. Clinical relationship of extrapyramidal symptoms and tardive dyskinesia. Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. Can J Psychiatry 1994;271:1058-66.
52. Ereshefsky L. Pharmacological profile of risperidone. Can J Psychiatry 1993;38(7 Suppl 3):S80-S88.
53. 2 receptors. Int Clin Psychopharmacol 1995;10:19-30.
54. 2 receptor occupancy with low-dose haloperidol treatment: a PET study. Am J Psychiatry 1996;153:948-50.
55. 2dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Life Sci 1995;57:PL103-7.
56. Keegan D. Risperidone: neurochemical, pharmacologic and clinical properties of a new antipsychotic drug. Can J Psychiatry 1994;39(Suppl 2):S46-S52.
57. Miller M, Chouinard G. Loss of striatal cholinergic neurons as a basis for tardive and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia. Biol Psychiatry 1993;34:713-38.
58. Remington GJ. The long-term treatment of schizophrenia. Can J Psychiatry 1995;40(Suppl 1):S3-S4.
59. Seeman P. Atypical neuroleptics: role of multiple receptors, endogenous dopamine, and receptor linkage. Acta Psychiatrica Scand 1990;358(Suppl):14-20.
60. Shriqui CL. Neuroleptic dosing and neuroleptic plasma levels in schizophrenia: determining the optimal regimen. Can J Psychiatry 1995;40(Suppl 2):S38-S48.
61. Sigmundson HK. Pharmacotherapy of schizophrenia: a review. Can J Psychiatry 1994;39(Suppl 2):S70-S75.
62. Villeneuve A. Pathophysiology and treatment of negative symptoms. Can J Psychiatry 1994;39(9 Suppl 2):S53-S58.
63. Clarke DE, Yaeger SF. Addressing emerging social needs of patients treated with new neuroleptics. J Psychosoc Nurs Ment Health Serv 1994;32:19-22.
64. MacEwan GW. New antipsychotic medications: Do research results relate to clinical practice? Can J Psychiatry 1993;38(Suppl 3):S75-S79.
65. Jeffries JJ. Ethical issues in drug selection for schizophrenia. Can J Psychiatry 1993;38(Suppl 3):S70-S74.
66. Naranjo CA, Herrmann N, Mittmann N, Bremner KE. Recent advances in geriatric psychopharmacology. Drugs Aging 1995;7:184-202.
67. Remington G. Understanding schizophrenia: the impact of novel antipsychotics. Can J Psychiatry 1995;40(Suppl 2):S29-S32.
68. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-35.
69. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 1995;166: 712-26.
70. Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 1996;153:466-76.
71. Sajatovic M, Ramirez LF, Vernon L, Brescan D, Simon M, Jurjus G. Outcome of risperidone therapy in elderly patients with chronic psychosis. Int J Psychiatry Med 1996;26(3):309-17.
72. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilisation? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992;146(4):473-81.
73. Bondolfi G, Baumann P, Dufour H. Treatment-resistant schizophrenia: clinical experience with new antipsychotics. Eur Neuropsychopharmacol 1996;6(Suppl 2):S21-S25.
74. Klieser E, Lehmann E, Kinzler E, Wurthmann, Heinrich K. Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia. J Clin Psychopharmacol 1994;15(1 Suppl 1):45S-51S.
75. Casey DE. Seroquel (quetiapine): preclinical and clinical finings of a new atypical antipsychotic. Exp Opin Invest Drugs 1996;5(8): 939-57.
76. Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasly C Jr, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17(5):407-17.
77. Beasley CM Jr, Tollefson GD, Tran PV. Efficacy of olanzapine: an overview of pivotal clinical trials. J Clin Psychiatry 1997;58 (Suppl 10):7-12.
78. Oh P, Einarson TR, Iskedjian M, Addis A, Lanctôt K. Pharmacoeconomic evaluation of risperidone and clozapine in chronic and treatment-resistant schizophrenia. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 1946.
79. Glazer WG, Ereshefsky L. A pharmacoeconomic model of out-patient antipsychotic therapy in "revoking door" schizophrenic patients. J Clin Psychiatry 1996;57(8):337-45.
80. Curtis VA, Kerwin RW. A risk-benefit assessment of risperidone in schizophrenia. Drug Safety 1995;12(2):139-45.